NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Marqeta, Inc. ("Marqeta" or the "Company") (NASDAQ:MQ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged […]

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Match Group, Inc. ("Match" or the "Company") (NASDAQ:MTCH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Dave INC. ("Dave" or the "Company") (NASDAQ:DAVE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dave and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sangamo and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson("J&J" or the "Company") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether J&J and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comâ?¯or 646-581-9980, ext.â?¯7980. The investigation concerns whether TransMedics and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nextracker Inc. ("Nextracker" or the "Company") (NASDAQ:NXT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nextracker and certain of its officers and/or directors have

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Vail Resorts, Inc. ("Vail Resorts" or the "Company") (NYSE:MTN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Vail Resorts and certain of its officers

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether 4D and certain of its officers and/or